In the BioHarmony Drug Report Database
Dolutegravir
Tivicay, Tivicay Pd (dolutegravir) is a small molecule pharmaceutical. Dolutegravir was first approved as Tivicay on 2013-08-12. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Tivicay’s patent is valid until 2029-12-08 (FDA).
Trade Name
|
Tivicay |
|---|---|
Common Name
|
dolutegravir |
ChEMBL ID
|
CHEMBL1229211 |
Indication
|
hiv infections |
Drug Class
|
Antivirals: integrase inhibitors |
Image (chem structure or protein)